21st May, 2012 -- ICON plc has made the following appointments:
Dr. Susan Anton, Director, Epidemiology and Risk Management Practice, ICON Late Phase & Outcomes Research
Dr. Susan Anton comes to ICON with over 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives. She joins ICON from Boehringer Ingelheim Pharmaceuticals Inc., where she was Director, US Medical Outcomes Research and Registries. In this role Dr. Anton provided strategic approach, design and analytic guidance for comparative effectiveness research, epidemiologic studies and health technology assessment within their Medical Outcomes Research & Registries division.
Prior to Boehringer Ingelheim, Dr. Anton directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb. Dr. Anton holds a Doctor of Public Health (Epidemiology) and a Master of Public Health from Columbia University, New York.
Dr. Pui Leung, Senior Clinical Research Physician, ICON Development Solutions
Dr Pui Man Leung has joined ICON as Senior Clinical Research Physician at ICON’s Clinical Pharmacology Unit in Manchester, UK.
Dr. Leung joins ICON with over 23 years of hospital and pharmaceutical industry experience in a variety of medical specialties including diabetes, endocrinology and general medicine. Prior to ICON, Dr. Leung gained 10 years of experience as a Senior Phase I Clinical Research Physician in two UK CROs and has been Principal Investigator in many trials with a variety of different study designs including First in Human studies. Before joining the pharmaceutical industry in 2002, Dr. Leung spent 13 years as a hospital physician in the UK’s National Health Service (NHS).
Dr. Leung is a fully qualified Pharmaceutical Physician and is listed in the UK’s Specialist Register in Pharmaceutical Medicine. He is a member of the Royal College of Physicians UK, where he is a member of the Examination Board at the Faculty of Pharmaceutical Medicine. Dr. Leung received his Doctor of Medicine from the University of Aberdeen and studied an MSc by Research in Rheumatology from the University of Manchester.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 8,500 employees, operating from 81 locations in 40 countries.
Further information is available at www.iconplc.com